Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Pfizer Inc. (
NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNNEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNNEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Valneva (VALN) To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Valneva (VALN) To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Valneva (VALN) To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Valneva SE (“Valneva” or “the Company”) (
NASDAQ: VALN) for violations of the securities laws.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNNEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (
NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Novavax’s dispute resolution and upcoming earnings callNovavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer.
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe.
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Pfizer Inc. (
NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
